Feline Transitional Cell Carcinoma: Welfare and Management

Key Facts

• TCC in cats most commonly arises in the trigone (bladder neck), causing obstructive signs
• Clinical signs include hematuria, pollakiuria (frequent urination), straining, and dysuria
• Medical management with piroxicam (NSAID with anti-tumor activity) provides palliation in many cats
• Surgical options are limited by tumor location at the trigone — complete resection is rarely possible
• Median survival with medical management is 4-6 months — quality of life during this period is the primary welfare goal

Welfare Considerations

TCC in cats creates significant welfare challenges through chronic urinary discomfort and the progressive nature of the disease. Hematuria is distressing, dysuria is painful, and urethral obstruction — if complete — is a life-threatening emergency. Welfare management centers on providing meaningful comfort through the palliative period. Piroxicam provides both analgesia and anti-tumor activity, making it a cornerstone of welfare-centered therapy. Owners benefit from honest prognosis communication and clear guidance on signs that indicate deteriorating quality of life requiring euthanasia consideration.

What You Can Do

• Seek veterinary evaluation promptly for any cat showing blood in urine or difficulty urinating
• Discuss piroxicam therapy with your vet — it improves both quality of life and has anti-tumor effects
• Implement quality-of-life scoring at monthly veterinary visits to objectively track the cat's comfort
• Plan for end-of-life care early — knowing when to request euthanasia reduces suffering from delayed decisions
• Ensure adequate pain management throughout the palliative period — urinary pain should not go untreated